Hashimoto Ryuya, Aso Kenichiro, Yata Keisuke, Fujioka Naoki, Tanaka Kazufumi, Moriyama Serika, Hirota Asato, Kawamura Juri, Maeno Takatoshi
Department of Ophthalmology, Toho University Sakura Medical Center, 564-1, Shimoshizu, Sakura 285-8741, Japan.
Diagnostics (Basel). 2024 Oct 18;14(20):2328. doi: 10.3390/diagnostics14202328.
BACKGROUND/OBJECTIVES: To evaluate the roles of choroidal blood flow (CBF) and choroidal thickness (CT) as predictors of macular edema recurrence in patients with treatment-naive non-ischemic branch retinal vein occlusion (BRVO) after intravitreal ranibizumab (IVR) injection.
Sixteen eyes from sixteen patients with treatment-naive non-ischemic BRVO treated with IVR, once initially and then as needed, were included in the study. CBF and CT in the subfovea, occlusive, and non-occlusive regions were measured via laser speckle flowgraphy and enhanced depth imaging optical coherence tomography over 12 months.
Baseline CT was significantly greater in the occlusive region (335 ± 72.1 µm) than in the non-occlusive region (274 ± 36.7 µm, = 0.028). CT in the occlusive region was reduced significantly after 1 week ( = 0.008), but CBF did not change significantly after IVR throughout the follow-up period ( > 0.05). The occlusive/non-occlusive region CBF ratio at baseline was significantly associated with the number of IVR injections over 12 months (mean 2.63) in patients with BRVO ( = 0.048).
Baseline CBF imbalance in eyes with treatment-naive BRVO may indicate the recurrence of macular edema after ranibizumab therapy.
背景/目的:评估脉络膜血流(CBF)和脉络膜厚度(CT)作为初治非缺血性视网膜分支静脉阻塞(BRVO)患者玻璃体内注射雷珠单抗(IVR)后黄斑水肿复发预测指标的作用。
本研究纳入16例初治非缺血性BRVO患者的16只眼,最初接受一次IVR治疗,随后根据需要进行治疗。通过激光散斑血流图和增强深度成像光学相干断层扫描在12个月内测量黄斑中心凹、阻塞区域和非阻塞区域的CBF和CT。
阻塞区域的基线CT(335±72.1μm)显著高于非阻塞区域(274±36.7μm,P = 0.028)。1周后阻塞区域的CT显著降低(P = 0.008),但在整个随访期内IVR后CBF无显著变化(P>0.05)。BRVO患者基线时阻塞/非阻塞区域CBF比值与12个月内IVR注射次数(平均2.63次)显著相关(P = 0.048)。
初治BRVO患者的基线CBF失衡可能预示雷珠单抗治疗后黄斑水肿复发。